Evidence map›Paper›PMID 31554818›Full record

ArticleNature communications2019

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

David P Labbé, Giorgia Zadra, Meng Yang, Jaime M Reyes, Charles Y Lin, Stefano Cacciatore, Ericka M Ebot, Amanda L Creech, Francesca Giunchi, Michelangelo Fiorentino and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Contemporary review of prognostic markers of prostate cancer from a pathologist perspective.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

David P LabbéDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8864-8765
Giorgia ZadraDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8123-1358
Meng YangDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jaime M ReyesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7895-2472
Charles Y LinDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Stefano CacciatoreCancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-7052-7156
Ericka M EbotDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Amanda L CreechThe Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
Francesca GiunchiPathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, Bologna, IT, Italy.
Michelangelo FiorentinoPathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, Bologna, IT, Italy.
Habiba ElfandyDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sudeepa SyamalaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Edward D KarolyMetabolon, Morrisville, NC, USA.
Mohammed AlshalalfaDecipher Biosciences, Vancouver, BC, Canada.
Nicholas ErhoDecipher Biosciences, Vancouver, BC, Canada.
Ashley RossJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Edward M SchaefferNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Ewan A GibbDecipher Biosciences, Vancouver, BC, Canada.
Mandeep TakharDecipher Biosciences, Vancouver, BC, Canada.
Robert B DenDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Jonathan LehrerDecipher Biosciences, Vancouver, BC, Canada.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic Rochester, Rochester, MN, USA.
Stephen J FreedlandDepartment of Surgery, Division of Urology, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Elai DavicioniDecipher Biosciences, Vancouver, BC, Canada.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Leigh EllisDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4739-5049
Jacob D JaffeThe Broad Institute of MIT and Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9845-1210
Anthony V DʼAmicoDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Philip W KantoffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
James E BradnerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2718-4415
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jorge E ChavarroDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Massimo LodaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. mloda@med.cornell.edu.
Myles BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. myles_brown@dfci.harvard.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2M
Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI HU, FRANK B · 1992 to 2021
$25.0M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Sleep Duration, Childhood Energy Balance, and Insulin Resistance in AdolescenceU54CA155626 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI STAMPFER, MEIR · 2011 to 2015
$9.6M
NUTRITIONAL BIOCHEMISTRY MARKERS OF CANCER AND MIR01CA042182 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MA, JING · 1986 to 2007
$5.3M
Hormones and Cytokines in CaP risk and recurrenceR01CA058684 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STAMPFER, MEIR · 1993 to 2006
$4.8M
Molecular Link Between Metabolic Syndrome and Prostate CancerR01CA131945 · NCI · DANA-FARBER CANCER INST · PI LODA, MASSIMO · 2008 to 2018
$4.0M
Growth Factors and Prostate Cancer RiskR01CA090598 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STAMPFER, MEIR · 2002 to 2008
$3.3M
NCI NIH HHS P01 CA163227NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA090381NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA058684NCI NIH HHS R01 CA090598NCI NIH HHS R01 CA097193NCI NIH HHS R01 CA131945NCI NIH HHS R01 CA141298NCI NIH HHS R01 CA187918NCI NIH HHS R01 CA215452NCI NIH HHS U01 CA167552NCI NIH HHS U54 CA155626NCI NIH HHS UM1 CA167552NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595NIDDK NIH HHS P30 DK046200
6 · The paper itself

Abstract

Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. Here, we demonstrate in a murine prostate cancer model, that high-fat diet (HFD) enhances the MYC transcriptional program through metabolic alterations that favour histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading to increased cellular proliferation and tumour burden. Saturated fat intake (SFI) is also associated with an enhanced MYC transcriptional signature in prostate cancer patients. The SFI-induced MYC signature independently predicts prostate cancer progression and death. Finally, switching from a high-fat to a low-fat diet, attenuates the MYC transcriptional program in mice. Our findings suggest that in primary prostate cancer, dietary SFI contributes to tumour progression by mimicking MYC over expression, setting the stage for therapeutic approaches involving changes to the diet.

Indexed as

AgedAnimalsCell Line, TumorCell ProliferationDiet, High-FatDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMetabolomeMice, TransgenicMiddle AgedProstatic NeoplasmsProto-Oncogene Proteins c-mycTumor BurdenProto-Oncogene Proteins c-myc

Identifiers

PMID31554818
PMCPMC6761092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.